TNF-α plays a role in sleep disturbance in patients with rotator cuff tear

Chul-Hyun Cho (oscho5362@dsmc.or.kr)
Keimyung University Dongsan Medical Center

Du Hwan Kim
Chung-Ang University

Eun Hee Baek
Keimyung University College of Medicine: Keimyung University School of Medicine

Du-Han Kim
Keimyung University College of Medicine: Keimyung University School of Medicine

Research article

Keywords: Rotator cuff, sleep, cytokine, tumor necrosis factor-α

Posted Date: October 5th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-936658/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background
The purpose of this study was to determine serum levels of sleep-related cytokines in patients with rotator cuff tear (RCT) and to investigate the correlations between serum levels of sleep-related cytokines and clinical scores.

Methods
Peripheral blood samples were collected from 63 study participants were divided into three groups: RCT patients with sleep disturbance (sleep disturbance group; SD group) \((n=21)\), RCT patients without sleep disturbance (normal sleep group; NS group) \((n=21)\), and patients with shoulder instability (control group) \((n=21)\). Serum concentration levels of sleep-related cytokines including interleukin-1α (IL-1α), IL-1β, IL-2, IL-6, IL-8, IL-10, and tumor necrosis factor-α (TNF-α) were measured via enzyme-linked immunosorbent assay. The associations between serum levels of sleep-related cytokines and clinical scores including the Visual Analogue Scale (VAS) pain score, the University of California at Los Angeles (UCLA) score, and the Pittsburgh Sleep Quality Index (PSQI) were analyzed.

Results
Serum concentration levels of TNF-α were significantly higher in the SD group compared with those of the NS and control groups \((P<0.001 \text{ and } 0.05)\). Serum levels of IL-8 and IL-10 were significantly higher in the SD group compared with those of control group \((P=0.01 \text{ and } 0.05)\), but did not differ significantly from that of the NS group \((P>0.05)\). Serum level of IL-6 was significantly lower in the SD group compared with those of the NS and control groups \((P<0.001 \text{ and } 0.01)\). There were no associations between serum levels of sleep-related cytokines and all clinical scores including VAS pain, UCLA, and PSQI scores (all \(P>0.05\)).

Conclusion
The current findings suggest that TNF-α may play a significant role in the pathophysiology of sleep disturbance in patients with RCT and be a possible therapeutic target to improve sleep disturbance in patients with RCT.

Introduction
Rotator cuff tear (RCT) is the most common cause of shoulder pain and functional disability leading to a considerable socioeconomic burden \([1, 2]\). Although intrinsic and extrinsic processes have been suggested as the underlying cause of RCT, the exact etiology and pathophysiology leading to the disease
remain controversial [3]. It has been widely reported that bursitis of the subacromial space (SAS) and synovitis of the glenohumeral joint (GHJ) both play a role in the development of shoulder pain in patients with RCT and that the severity correlate with the pain intensity [4–7]. Several studies have reported that clinical symptoms and disease progression are involved in overexpression of proinflammatory and pain-related cytokines in the shoulder joint including subacromial bursa, joint capsule, and joint fluid [3–8]. Additionally, previous findings indicate that inflammatory mediators such as interleukin-1α (IL-1α), IL-1β, IL-6, IL-8, tumor necrosis factor-α (TNF-α), cyclooxygenase (COX)-1, and COX-2 play an important role in inflammation and pain due to RCT [3–8].

Night pain is a common symptom in patients with shoulder problems including RCT, frozen shoulder, and osteoarthritis [9, 10]. Cho et al. [9] found that 81.5% of patients with chronic shoulder pain reported sleep disturbance due to night pain and the prevalence was higher than patients with low back pain, fibromyalgia, or rheumatoid arthritis. However, the etiology and pathophysiology for the occurrence of night pain and sleep disturbance in these patients remain largely unknown.

Sleep regulation is complex and associated with changes in the expression of numerous molecules that are directly involved in sleep [11–15]. Sleep disturbance has been associated with changes in cytokines, which are molecules used for intercellular communication by the immune system. Emerging evidence suggested that sleep disturbance can sensitize or dysregulate inflammatory pathways [16]. Furthermore, previous studies have demonstrated that sleep disturbance in various diseases is associated with altered serum levels of sleep-related cytokines including IL-1, IL-2, IL-6, IL-8, IL-10, and TNF-α [16–23]. These cytokines are also involved in inflammatory, anti-inflammatory, and pain pathways.

Sleep problems with night pain in patients with shoulder disease can create a vicious cycle of persistent pain perception, sleep disturbance, daytime dysfunction, behavioral or emotional changes, depression, and anxiety [9, 10]. Sleep disturbance is a clinically significant target as it can be effectively treated. Despite the clinical importance, the biological underlying mechanism for sleep disturbance in patients with RCT is poorly understood. No prior studies have investigated serum levels of sleep-related cytokines to elucidate the pathophysiologic process of sleep disturbance in patients with RCT.

The primary purpose of this study was to determine serum concentration levels of sleep-related cytokines in patients with RCT. The secondary purpose was to investigate the correlations between serum levels of sleep-related cytokines and clinical scores. This study was conducted to test the hypothesis that serum levels of sleep-related cytokines are altered in patients with RCT who are experiencing pain-related sleep disturbance.

Materials And Methods

Subjects

This research has been approved by the IRB of the authors’ affiliated institutions and informed consent was obtained from all patients. Study subjects included 21 patients with sleep disturbance (sleep
disturbance group; SD group) and 21 patients without sleep disturbance (normal sleep group; NS group) who were undergoing arthroscopic surgery for RCT and 21 patients (control group) who were undergoing arthroscopic labral repair for shoulder instability. Exclusion criteria included: 1) a history of insomnia. 2) a history of psychiatric disorders, and 3) the presence of antipsychotics or sedative drug medication.

Assessments and Instruments

Before surgery, 42 participants with RCT were evaluated using the Visual Analogue Scale (VAS) pain score, the University of California at Los Angeles (UCLA) score, and the Pittsburgh Sleep Quality Index (PSQI). This PSQI is a 19-item, self-report, questionnaire-based index that obtains information from the patient regarding sleep habits during the preceding month to measure subjective sleep quality [24]. This questionnaire scores subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Sleep disturbance was defined as a total score of $\geq 5$.

Enzyme-Linked Immunosorbent Assay

Peripheral blood samples were collected in the operating room prior to surgery, between 8 a.m. and 12 p.m. Collected blood samples were centrifuged to isolate the serum, which was harvested and stored at -20°C for batch analysis. The sleep-related serum markers selected for this study included IL-1$\alpha$, IL-1$\beta$, IL-2, IL-6, IL-8, IL-10, and TNF-$\alpha$ based on results from previous studies [16–23].

Serum concentration levels of sleep-related cytokines including IL-1$\alpha$, IL-1$\beta$, IL-2, IL-6, IL-8, IL-10, and TNF-$\alpha$ were detected using a Magnetic Luminex Screening Assay (Luminex, Austin, TX, USA) according to the manufacturer's protocol. The microparticle cocktail (50 µl) was added into a 96 well plate, followed by 50 µl of standard and diluted samples. The microplates were incubated for 2 h at RT with gentle shaking. A volume of 50 µl diluted biotin antibody cocktail and diluted streptavidin-phycoerythrin were added and incubated at RT with shaking. The microparticles were re-suspended with 100 µl wash buffer. Following incubation for 2 min, the microplates were read using the Luminex. Serum markers were assayed in duplicate and all values were expressed as the mean of the two measurements.

Statistical Methods

Statistical analysis of data was performed using SPSS (version 20.0; IBM, Armonk, NY, USA). Data were analyzed using the Mann-Whitney U test and Chi-square test. To determine the correlations between serum levels of sleep-related cytokines and clinical scores, the Kendal tau B correlation analysis was used. The results are expressed mean values ± standard deviation (SD) and were considered significantly different when the two-tailed $P$ value was $< 0.05$.

Results

The mean age of patients was 56.9 ± 8.6 years in the SD group, 55.7 ± 7.3 years in the NS group, and 30.1 ± 13.1 years in the control group. There were 12 women and 9 men in the SD group, 11 women and 10 men in the NS group, and 3 women and 18 men in the control group. No statistically significant
differences were found between the SD group and the NS group regarding age, sex, dominant arm, diabetes mellitus, duration of symptoms, preoperative stiffness, tear size, preoperative VAS pain score, or preoperative UCLA score ($P > 0.05$). Significant differences were found in the mean preoperative PSQI score which was 7.4 ± 2.9 in the SD group and 3.0 ± 1.1 in the NS group ($P < 0.001$) (Table 1).

**Table 1**  
Demographic and clinical data

|                          | Sleep disturbance group ($n = 21$) | Normal sleep group ($n = 21$) | $P$ value |
|--------------------------|-----------------------------------|-------------------------------|-----------|
| Age, year                | 56.9 ± 8.6                        | 55.7 ± 7.3                    | 0.521     |
| Sex, male/female, n      | 9/12                              | 10/11                         | 0.757     |
| Dominant arm. yes/no, n  | 14/7                              | 13/8                          | 0.747     |
| Diabetes mellitus, yes/no, n | 4/17                  | 2/19                          | 0.663     |
| Duration of symptoms, months | 29.09 ± 40.1                     | 28.5 ± 41.3                   | 0.533     |
| Preoperative stiffness. yes/no, n | 8/13                  | 10/11                         | 0.284     |
| Preoperative VAS pain score | 6.9 ± 1.2                      | 6.1 ± 1.8                     | 0.071     |
| Preoperative UCLA score  | 13.5 ± 4.3                       | 13.9 ± 5.1                    | 0.640     |
| Preoperative PSQI score  | 7.4 ± 2.9                        | 3.0 ± 1.1                     | < 0.001*  |

**VAS visual analog scale, UCLA University of California; Los Angeles, PSQI Pittsburgh Sleep Quality Index**  

*Statistically significant, $P < 0.05$.

**IL-6**

Serum concentration levels of IL-6 were 0.31 ± 0.31 pg/mL in the SD group, 1.26 ± 0.64 pg/mL in the NS group, and 2.75 ± 1.45 pg/mL in the control group. Serum level of IL-6 was significantly lower in the SD group compared with those of the NS and control groups ($P = < 0.001$ and 0.01) (Fig. 1).

**IL-8**

Serum concentration levels of IL-8 were 22.30 ± 6.04 pg/mL in the SD group, 17.62 ± 2.88 pg/mL in the NS group, and 13.26 ± 2.26 pg/mL in the control group. Serum levels of IL-8 were significantly higher in the SD group compared with those of the control group ($P = 0.01$), but did not differ significantly from that of the NS group ($P > 0.05$) (Fig. 2).

**IL-10**
Serum concentration levels of IL-10 were 2.94 ± 0.42 pg/mL in the SD group, 2.93 ± 0.28 pg/mL in the NS group, and 2.65 ± 0.38 pg/mL in the control group. Serum levels of IL-10 were significantly higher in the SD group compared with those of the control group ($P = 0.05$), but did not differ significantly from that of the NS group ($P > 0.05$) (Fig. 3).

**TNF-α**

Serum concentration levels of TNF-α were 4.24 ± 0.56 pg/mL in the SD group, 3.08 ± 0.58 pg/mL in the NS group, and 3.67 ± 0.58 pg/mL in the control group. Serum levels of TNF-α were significantly higher in the SD group compared with those of the NS and control groups ($P < 0.001$ and $0.05$) (Fig. 4).

### Correlations between serum levels of sleep-related cytokines and clinical scores

Correlation analyses revealed that there were no associations between serum levels of sleep-related cytokines and all clinical scores including VAS pain, UCLA, and PSQI scores ($P > 0.05$) (Table 2).

| Correlation analyses between serum levels of sleep-related cytokines and clinical scores |
|---------------------------------|-----------------|-----------------|
|                                 | VAS pain score  | UCLA score      | PSQI score |
| IL-6 Coefficient               | 0.177           | 0.003           | 0.079      |
| $P$ value                      | 0.482           | 0.992           | 0.755      |
| IL-8 Coefficient               | -0.794          | 0.609           | 0.580      |
| $P$ value                      | 0.059           | 0.200           | 0.228      |
| IL-10 Coefficient              | -0.349          | 0.392           | -0.050     |
| $P$ value                      | 0.131           | 0.087           | 0.835      |
| TNF-α Coefficient              | 0.434           | -0.418          | 0.330      |
| $P$ value                      | 0.330           | 0.350           | 0.469      |

**Discussion**

This present study was conducted to test the hypothesis that serum levels of sleep-related cytokines are involved in sleep disturbance in patients with RCT. To the best of our knowledge, this is the first study to investigate levels of sleep-related cytokines in patients with RCT. Our study demonstrated that serum concentration levels of TNF-α were significantly higher in the SD group compared with those of the NS and control groups. There were no associations between serum levels of sleep-related cytokines and...
clinical scores including VAS pain, UCLA, and PSQI scores. Our findings support a significant role of TNF-α in the pathophysiology of sleep disturbance as well as pain mechanism in patients with RCT, suggesting that TNF-α may be a therapeutic target for improving sleep disturbance in patients with RCT.

Numerous studies have demonstrated the association between poor sleep, inflammatory cytokines, and pain [11, 12, 15–17, 22]. Clinton et al. [11] reported that sleep deprivation and altered cytokine levels are associated with increased sensitivity to pain with sleepiness and rebound sleep. Heffner et al. [16] also reported that inflammatory and pain pathways can be the underlying mechanism responsible for the association between chronic pain and sleep disturbance. In patients with chronic pain such as fibromyalgia, chronic low back pain, osteoarthritis, or chronic fatigue syndrome, sleep disturbance was found to have significant associations with altered levels of cytokines [16]. Previous studies have demonstrated that sleep disturbance in various diseases is associated with altered circulating levels of sleep-related cytokines including IL-1, IL-2, IL-6, IL-8, IL-10, and TNF-α [16–23]. These cytokines are also involved in inflammatory, anti-inflammatory, and pain pathways. Especially, IL-1α, IL-1β, IL-6, IL-8, and TNF-α have been found to play an important role in inflammation and pain due to RCT [3–8]. In comprehensive review of results from previous studies related sleep disturbance in various diseases, the present study included IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, and TNF-α as sleep-related serum markers.

IL-1, IL-6, and TNF-α are pleiotropic, serving both physiologic and pathological functions including modulation of inflammation, sleep, and mood [11]. Several studies reported that sleep deprivation is associated with increased levels of IL-6 and TNF-α [12, 20]. Additionally, poor sleep quality and increased frequency of sleep disturbance have been associated with elevated levels of IL-2 and IL-6 [12, 20]. Lee et al. [20] found that elevated levels of pro-inflammatory cytokines such as IL-6 and TNF-α were associated with poorer sleep quality in patients with schizophrenia. Cytokines including IL-1 and TNF-α partake in non-rapid eye movement sleep (NREMS) regulation under physiological and inflammatory conditions [11, 13].

Rockstrom et al. [15] found that TNF-α is involved in sleep regulation acting within an extensive tightly orchestrated biochemical network impacting sleep in health and disease. Clinton et al. [11] also described that cytokines such as IL-1 and TNF-α play in sleep regulation as they are currently the best-characterized sleep regulatory substances. Circulating levels of TNF-α are altered in many pathologies that exhibit sleep disturbances including chronic inflammation, rheumatoid arthritis, insomnia, and chronic fatigue syndrome [14]. Rockstom et al. [15] reported that high circulating levels of TNF-α are associated with sleep problems and normalization of high TNF-α level improves sleep. Many symptoms induced by sleep loss, e.g. sleepiness, fatigue, poor cognition, enhanced pain sensitivity, can be elicited with an injection of exogenous IL-1 or TNF-α [11, 13, 14]. Clinically available inhibitors of IL-1 and TNF-α reduce the sleepiness and fatigue associated with rheumatoid arthritis and sleep apnea [11]. The present study demonstrated that serum concentration levels of TNF-α were significantly higher in the SD group compared with those of the NS and control groups. Our findings support that TNF-α may play a significant role in pathophysiology of sleep disturbance as well as pain mechanism in patients with RCT and be a possible therapeutic target to improve sleep disturbance.
Heffner et al. [17] found that poorer sleep quality is associated with higher circulating levels of IL-6 in patients with chronic low back pain. Additionally, Ji et al. [18] found that IL-6 levels are positively correlated with cluster symptoms of pain, fatigue, depression, and sleep disturbance in patients with cancer. Wang et al. [23] found elevated IL-6 levels are associated with sleep disturbance in patients with major depressive disorder. However, the present study found that serum levels of IL-6 were significantly lower in the SD group compared with those of the NS and control groups. These are apparently contradictory results compared to those of previous studies. Pro-inflammatory and anti-inflammatory cytokines influence physiological sleep and sleep responses to pathological insult [15]. IL-8 is a multifunctional chemokine that has a strong influence on the activation, regulation, and chemotactic effect of neutrophils and is significantly increased in patients with sleep disorders and various inflammatory conditions [21]. IL-10, also known as human cytokine synthesis inhibitory factor, is an anti-inflammatory cytokine. Kim et al. [19] found that circulating IL-10 levels in those with idiopathic rapid eye movement sleep (REMS) disorder were significantly upregulated compared to those without idiopathic REMS disorder. Park et al. [22] found that increased IL-10 levels were related to low sleep quality in patients with temporomandibular disorder, supporting the finding that anti-inflammatory cytokines have a sleep-disrupting effect. Although the present study revealed serum levels of IL-8 and IL-10 were significantly higher in the SD group compared with those of the control group, differences were not significant when compared to the NS group. In light of these findings, further well-designed studies are needed to elucidate the connections between sleep disturbance and sleep-related cytokines such as IL-6, IL-8, and IL-10 in patients with RCT.

Recently, Ha et al. [10] reported melatonin may play a role as a mediator of night pain in patients with RCT or frozen shoulder. They found that melatonin increases the production of proinflammatory and pain-related cytokines such as IL-1α, IL-1β, IL-2, IL-6, and TNF-α [10]. Circadian changes in melatonin levels may be an important contributor to the pathophysiology and treatment of patients with RCT. Further studies are needed to provide a better understanding of the role of melatonin and cytokines on symptoms including pain, inflammation, and sleep disturbance.

This study has several limitations. First, the control group was not matched for age and sex when compared to the SD group. However, the NS group was provided as an additional comparison group. Second, serum concentration levels of IL-1α, IL-1β, IL-2 were not measured as any value was out of the standard curve. Third, this is a cross-sectional study, and serial changes of sleep-related cytokines were not compared with symptoms after the operative procedure. Future prospective longitudinal studies with a wider spectrum of sleep-related mediators are needed to clarify these issues.

**Conclusion**

The current findings suggest that TNF-α may play a significant role in the pathophysiology of sleep disturbance in patients with RCT and be a possible therapeutic target to improve sleep disturbance in patients with RCT.
Abbreviations

RCT: Rotator cuff tear; SAS: Subacromial space; GHJ: Glenohumeral joint; IL-1α: Interleukin-1α; TNF-α: Tumor necrosis factor-α; COX: Cyclooxygenase; SD group: Sleep disturbance group; NS group: Normal sleep group; VAS: Visual Analogue Scale; UCLA: University of California at Los Angeles; PSQI: Pittsburgh Sleep Quality Index; SD: Standard deviation; NREMS: in non-rapid eye movement sleep; REMS: Rapid eye movement sleep

Declarations

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Keimyung University Dongsan Hospital (IRB No: 202004074)

Consent for publication

Not applicable

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Competing interests

The authors declare that they have no competing interests.

Funding

Following are sources of funding for this work: Support was received from the National Research Foundation of Korea, funded by the Korean government (grant number 2021R1F1A1047546 and 2017R1D1A1B03035113).

Authors' contributions

CHC and DHwanK performed research design and manuscript drafting. EHB and DHanK performed experiment and data analysis. All authors have read and approved the final submitted manuscript.

Acknowledgements

Chul-Hyun Cho and Du Hwan Kim are co-first authors. The biospecimens and data used for this study were provided by the Biobank of Keimyung University Dongsan Hospital, a member of the Korea Biobank Network.

References
1. Lee KW, Lee GS, Yang DS, Park SH, Chun YS, Choy WS. Clinical Outcome of Arthroscopic Partial Repair of Large to Massive Posterosuperior Rotator Cuff Tears: Medialization of the Attachment Site of the Rotator Cuff Tendon. Clin Orthop Surg. 2020;12(3):353–63. https://doi.org/10.4055/cios19126.

2. Oh JH, Lee YH, Lee TH, Jang SI, Kwon J. The Natural History of High-Grade Partial Thickness Rotator Cuff Tears: The Conversion Rate to Full Thickness Tears and Affecting Factors. Clin Orthop Surg. 2020;12(4):514–20. https://doi.org/10.4055/cios19167.

3. Kim SK, Kim HN, Moon ES, Lim KY, Cho NY, Kim MS. Inflammatory Cytokine Expressions of the Subacromial Bursitis and Glenohumeral Joint Synovitis in the Patients with Full Thickness Rotator Cuff Tear. Clin Shoulder Elbow. 2011;14(2):172–8. https://doi.org/10.5397/CiSE.2011.14.2.172.

4. Blaine TA, Kim YS, Voloshin I, Chen D, Murakami K, Chang SS, et al. The molecular pathophysiology of subacromial bursitis in rotator cuff disease. J Shoulder Elbow Surg. 2005;14(1 Suppl S):84s-9s. https://doi.org/10.1016/j.jse.2004.09.022.

5. Gotoh M, Hamada K, Yamakawa H, Yanagisawa K, Nakamura M, Yamazaki H, et al. Interleukin-1-induced glenohumeral synovitis and shoulder pain in rotator cuff diseases. J Orthop Res. 2002;20(6):1365–71. https://doi.org/10.1016/s0736-0266(02)00063-3.

6. Okamura K, Kobayashi T, Yamamoto A, Shitara H, Osawa T, Ichinose T, et al. Shoulder pain and intra-articular interleukin-8 levels in patients with rotator cuff tears. Int J Rheum Dis. 2017;20(2):177–81. https://doi.org/10.1111/1756-185x.12581.

7. Voloshin I, Gelinas J, Maloney MD, O'Keefe RJ, Bigliani LU, Blaine TA. Proinflammatory cytokines and metalloproteases are expressed in the subacromial bursa in patients with rotator cuff disease. Arthroscopy. 2005;21(9):1076.e1-.e9. https://doi.org/10.1016/j.arthro.2005.05.017.

8. Yamazaki H, Ochiai N, Kenmoku T, Ohtori S, Sasho T, Miyagi M, et al. Assessment of pain-related behavior and pro-inflammatory cytokine levels in the rat rotator cuff tear model. J Orthop Res. 2014;32(2):286–90. https://doi.org/10.1002/jor.22486.

9. Cho CH, Jung SW, Park JY, Song KS, Yu KI. Is shoulder pain for three months or longer correlated with depression, anxiety, and sleep disturbance? J Shoulder Elbow Surg. 2013;22(2):222–8. https://doi.org/10.1016/j.jse.2012.04.001.

10. Ha E, Lho YM, Seo HJ, Cho CH. Melatonin Plays a Role as a Mediator of Nocturnal Pain in Patients with Shoulder Disorders. J Bone Joint Surg Am. 2014;96(13):e108. https://doi.org/10.2106/jbjs.M.01011.

11. Clinton JM, Davis CJ, Zielinski MR, Jewett KA, Krueger JM. Biochemical regulation of sleep and sleep biomarkers. J Clin Sleep Med. 2011;7(5 Suppl):38–42. https://doi.org/10.5664/jcsm.1360.

12. Irwin MR. Sleep and inflammation: partners in sickness and in health. Nat Rev Immunol. 2019;19(11):702–15. https://doi.org/10.1038/s41577-019-0190-z.

13. Krueger JM. The role of cytokines in sleep regulation. Curr Pharm Des. 2008;14(32):3408–16. https://doi.org/10.2174/138161208786549281.
14. Krueger JM, Clinton JM, Winters BD, Zielinski MR, Taishi P, Jewett KA, et al. Involvement of cytokines in slow wave sleep. Prog Brain Res. 2011;193:39–47. https://doi.org/10.1016/b978-0-444-53839-0.00003-x.

15. Rockstrom MD, Chen L, Taishi P, Nguyen JT, Gibbons CM, Veasey SC, et al. Tumor necrosis factor alpha in sleep regulation. Sleep Med Rev. 2018;40:69–78. https://doi.org/10.1016/j.smrv.2017.10.005.

16. Heffner KL, France CR, Ashrafioun L, Quiñones M, Walsh P, Maloney MD, et al. Clinical Pain-related Outcomes and Inflammatory Cytokine Response to Pain Following Insomnia Improvement in Adults With Knee Osteoarthritis. Clin J Pain. 2018;34(12):1133–40. https://doi.org/10.1097/ajp.0000000000000644.

17. Heffner KL, France CR, Trost Z, Ng HM, Pigeon WR. Chronic low back pain, sleep disturbance, and interleukin-6. Clin J Pain. 2011;27(1):35–41. https://doi.org/10.1097/ajp.0b013e3181eef761.

18. Ji YB, Bo CL, Xue XJ, Weng EM, Gao GC, Dai BB, et al. Association of Inflammatory Cytokines With the Symptom Cluster of Pain, Fatigue, Depression, and Sleep Disturbance in Chinese Patients With Cancer. J Pain Symptom Manage. 2017;54(6):843–52. https://doi.org/10.1016/j.jpainsymman.2017.05.003.

19. Kim R, Jun JS, Kim HJ, Jung KY, Shin YW, Yang TW, et al. Peripheral Blood Inflammatory Cytokines in Idiopathic REM Sleep Behavior Disorder. Mov Disord. 2019;34(11):1739–44. https://doi.org/10.1002/mds.27841.

20. Lee EE, Ancoli-Israel S, Eyler LT, Tu XM, Palmer BW, Irwin MR, et al. Sleep Disturbances and Inflammatory Biomarkers in Schizophrenia: Focus on Sex Differences. Am J Geriatr Psychiatry. 2019;27(1):21–31. https://doi.org/10.1016/j.jagp.2018.09.017.

21. Ming H, Tian A, Liu B, Hu Y, Liu C, Chen R, et al. Inflammatory cytokines tumor necrosis factor-α, interleukin-8 and sleep monitoring in patients with obstructive sleep apnea syndrome. Exp Ther Med. 2019;17(3):1766–70. https://doi.org/10.3892/etm.2018.7110.

22. Park JW, Chung JW. Inflammatory Cytokines and Sleep Disturbance in Patients with Temporomandibular Disorders. J Oral Facial Pain Headache. 2016;30(1):27–33. https://doi.org/10.11607/ofph.1367.

23. Wang M, Wei J, Yang X, Ni P, Wang Y, Zhao L, et al. The level of IL-6 was associated with sleep disturbances in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2019;15:1695–700. https://doi.org/10.2147/ndt.S202329.

24. Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res. 2002;53(3):737–40. https://doi.org/10.1016/s0022-3999(02)00330-6.

Figures
Figure 1

Serum concentration levels of IL-6. The error bars indicate the standard deviation. *P < 0.05; **P < 0.001
Figure 2

Serum concentration levels of IL-8. The error bars indicate the standard deviation. *P < 0.05; **P < 0.001
Figure 3

Serum concentration levels of IL-10. The error bars indicate the standard deviation. *P < 0.05; **P < 0.001
Figure 4

Serum concentration levels of TNF-α. The error bars indicate the standard deviation. *P < 0.05; **P < 0.001